Status: Recruiting
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
Participants needed: 400
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: TargetCancer FoundationUpdated: May 26, 2026Locations: 1
Eligibility criteria
Provision of signed and dated informed consent form. [+11]
Participants who are unable to provide informed consent. [+6]